{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:36:44Z","timestamp":1785411404893,"version":"3.56.0"},"reference-count":56,"publisher":"American Society for Microbiology","issue":"12","license":[{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100016956","name":"Melinta Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016956","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2025,12,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Carbapenem-resistant\n                      <jats:italic toggle=\"yes\">Enterobacterales<\/jats:italic>\n                      (CREs) are recognized as an urgent public threat by the Centers for Disease Control and Prevention. This study assesses the activity of humanized serum concentrations for meropenem (2 g Q8h), meropenem-vaborbactam (4 g Q8h), and ceftazidime-avibactam (2.5 g Q8h) against carbapenemase-producing (CP) (AR-1046\n                      <jats:italic toggle=\"yes\">\n                        <jats:sub>bla<\/jats:sub>\n                      <\/jats:italic>\n                      <jats:sub>KPC-3<\/jats:sub>\n                      ) and non-CP (AR-8\n                      <jats:italic toggle=\"yes\">\n                        <jats:sub>bla<\/jats:sub>\n                      <\/jats:italic>\n                      <jats:sub>ACT-15<\/jats:sub>\n                      )\n                      <jats:italic toggle=\"yes\">Enterobacter cloacae<\/jats:italic>\n                      isolates in a 120 h\n                      <jats:italic toggle=\"yes\">in vitro<\/jats:italic>\n                      pharmacodynamic model. Additionally, we compared antimicrobial administration as a bolus or extended infusion for each isolate and treatment. For the CP strain, all treatments with meropenem-vaborbactam and ceftazidime-avibactam were bacteriostatic through 24 h. Extended-infusion meropenem-vaborbactam exhibited the most prolonged bacteriostatic activity and was significantly more effective than ceftazidime-avibactam at 120 h (0.92 log\n                      <jats:sub>10<\/jats:sub>\n                      lower mean colony count compared to extended-infusion ceftazidime-avibactam,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001). For the non-CP strain, all simulated treatments demonstrated initial bactericidal activity through 24 h, except for ceftazidime-avibactam bolus administration. Meropenem and meropenem-vaborbactam, administered as bolus dosing, each maintained significantly greater bacterial colony count reductions compared to extended infusion through 120 h against non-CP CRE (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.01). No significant differences were found between bolus and extended infusion for ceftazidime-avibactam (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.08). Resistance development was observed following treatment with meropenem monotherapy (minimum inhibitory concentrations increasing to &gt;32 \u00b5g\/mL for the non-CP isolate with extended infusion and to &gt;32 \u00b5g\/mL for the CP isolate with bolus and extended-infusion treatments) and ceftazidime-avibactam (minimum inhibitory concentration increase from 2 to 16 \u03bcg\/mL with bolus dosing against the CP isolate). Meropenem-vaborbactam exposure did not result in the emergence of antimicrobial resistance in any of the tested models.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1128\/aac.00906-25","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T14:11:22Z","timestamp":1763561482000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":0,"title":["Unlocking potentials: the impact of meropenem, meropenem-vaborbactam, and ceftazidime-avibactam in combating carbapenem-resistant\n                    <i>Enterobacter cloacae<\/i>"],"prefix":"10.1128","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-4842-3381","authenticated-orcid":true,"given":"Thomas","family":"Lavoie","sequence":"first","affiliation":[{"name":"Infectious Diseases Research Program, Providence Veterans Affairs Medical Center","place":["Providence, USA"]},{"id":[{"id":"https:\/\/ror.org\/013ckk937","id-type":"ROR","asserted-by":"publisher"}],"name":"College of Pharmacy, University of Rhode Island","place":["Kingston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Sierra","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/013ckk937","id-type":"ROR","asserted-by":"publisher"}],"name":"College of Pharmacy, University of Rhode Island","place":["Kingston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1942-3033","authenticated-orcid":false,"given":"Katie","family":"Daffinee","sequence":"additional","affiliation":[{"name":"Infectious Diseases Research Program, Providence Veterans Affairs Medical Center","place":["Providence, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4780-6215","authenticated-orcid":true,"given":"Jason M.","family":"Pogue","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00jmfr291","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Clinical Pharmacy, University of Michigan College of Pharmacy","place":["Ann Arbor, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brahim","family":"Achour","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/013ckk937","id-type":"ROR","asserted-by":"publisher"}],"name":"College of Pharmacy, University of Rhode Island","place":["Kingston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9650-4275","authenticated-orcid":true,"given":"Kerry","family":"LaPlante","sequence":"additional","affiliation":[{"name":"Infectious Diseases Research Program, Providence Veterans Affairs Medical Center","place":["Providence, USA"]},{"id":[{"id":"https:\/\/ror.org\/013ckk937","id-type":"ROR","asserted-by":"publisher"}],"name":"College of Pharmacy, University of Rhode Island","place":["Kingston, USA"]},{"name":"Center of Innovation- Long-term Services and Supports, Providence Veterans Affairs Medical Center","place":["Providence, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","unstructured":"Centers for Disease Control and Prevention (CDC). 2019. Control C.f.D. and Prevention CDC Antibiotic Resistance Threats in the United States 2019. Available from: https:\/\/www.cdc.gov\/drugresistance\/biggest-threats.html"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae403"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00883-17"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/evidoa2200131"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2021.05.079"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.4212\/cjhp.v67i3.1358"},{"key":"e_1_3_3_8_2","unstructured":"Centers for Disease Control and Prevention. 2025 Carbapenem-Resistant Enterobacterales (CRE). Antibiotic Resistance & Patient Safety Portal. Available from: https:\/\/arpsp.cdc.gov\/profile\/arln\/cre?hidden=&tabsection-166=0"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad046"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30755-8"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.106126"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms11061491"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1177\/0885066609335660"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid2305.162034"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae403"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-022-00682-0"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-018-0214-1"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw636"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix783"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy576"},{"key":"e_1_3_3_21_2","volume-title":"Performance standards for antimicrobial susceptibility testing, M100","author":"CLSI","year":"2023","unstructured":"CLSI. 2023. Performance standards for antimicrobial susceptibility testing, M100. 33rd ed. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"33"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12585"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02105-19"},{"key":"e_1_3_3_24_2","unstructured":"Avycaz [package insert]. 2015. Cincinnati OH Forest Pharmaceuticals Inc."},{"key":"e_1_3_3_25_2","unstructured":"Vabomere [package insert]. 2017. Parsippany NJ The Medicines Company Inc."},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-018-0241-0"},{"key":"e_1_3_3_27_2","unstructured":"Clinical and Laboratory Standards Institute. 2015. Performance Standards for Antimicrobial Susceptibility Testing. Wayne Pennsylvania USA CLSI."},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.13.4.570"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.18.3.377"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01680-20"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03126-15"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.12.4665-4672.2004"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02790-13"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.4.1298-1303.2006"},{"key":"e_1_3_3_35_2","unstructured":"Centers for Disease Control and Prevention. 2021. \u201c2019 Antibiotic Resistance Threats Report.\u201d Centers for Disease Control and Prevention. Available from: https:\/\/www.cdc.gov\/DrugResistance\/Biggest-Threats.html"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00002-19"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz194"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1086\/510590"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02130-21"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S469313"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02446-17"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw480"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tim.2018.10.007"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13104-019-4177-4"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlad022"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofv050"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.11.4760-4762.2005"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02414-21"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa503"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy492"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02313-19"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz1131"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02497-17"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab371"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad428"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01969-17"},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy790"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00906-25","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00906-25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T14:05:09Z","timestamp":1765375509000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.00906-25"}},"subtitle":[],"editor":[{"given":"James E.","family":"Leggett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,12,10]]},"references-count":56,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12,10]]}},"alternative-id":["10.1128\/aac.00906-25"],"URL":"https:\/\/doi.org\/10.1128\/aac.00906-25","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,10]]},"assertion":[{"value":"2025-06-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00906-25"}}